Payment overview · 2025
General Payments
$147.55
9 reported records · 3 companies
Healthcare provider profile · identity verified
Tomas E Vigo Paredes, MD
Allopathic & Osteopathic Physicians|General Practice · CHAPMANVILLE, WV · NPI 1851395834
Verified facts
What the public records show
CMS Open Payments records show Tomas E Vigo Paredes, MD received $147.55 in general payments during 2025 across 9 reported records.
AstraZeneca Pharmaceuticals LP accounted for 50.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $74.04 | 50.2% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.86 | 25.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $35.65 | 24.2% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $147.55 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $45.31 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.86 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $35.65 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.73 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 77 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
77 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 584 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 445 | 77 |
| Lisinopril | Lisinopril | 393 | 66 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 324 | 18 |
| Omeprazole | Omeprazole | 311 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 281 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 275 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 262 | 47 |
| Alprazolam | Alprazolam | 237 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 226 | 46 |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 191 | suppressed |
| Metformin Hcl | Metformin Hcl | 178 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 163 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 155 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 149 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 148 | 18 |
| Buspirone Hcl | Buspirone Hcl | 135 | 22 |
| Losartan Potassium | Losartan Potassium | 126 | 20 |
| Tramadol Hcl | Tramadol Hcl | 122 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 118 | 23 |
| Potassium Chloride | Potassium Chloride | 113 | 24 |
| Meloxicam | Meloxicam | 106 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 105 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 104 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 17 |
| Allopurinol | Allopurinol | 91 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 16 |
| Ondansetron Odt | Ondansetron | 88 | 14 |
| Furosemide | Furosemide | 87 | 18 |
| Naproxen | Naproxen | 84 | 14 |
| Ibuprofen | Ibuprofen | 79 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 77 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 77 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 75 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 73 | 15 |
| Montelukast Sodium | Montelukast Sodium | 71 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | 11 |
| Simvastatin | Simvastatin | 67 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 59 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 13 |
| Baclofen | Baclofen | 56 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | 18 |
| Lorazepam | Lorazepam | 55 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 54 | suppressed |
| Clonazepam | Clonazepam | 54 | suppressed |
| Eliquis | Apixaban | 54 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 53 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 51 | 22 |
| Farxiga | Dapagliflozin Propanediol | 48 | suppressed |
| Pregabalin | Pregabalin | 48 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 47 | suppressed |
| Diazepam | Diazepam | 46 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 46 | 20 |
| Mirtazapine | Mirtazapine | 46 | 12 |
| Promethazine Hcl | Promethazine Hcl | 46 | suppressed |
| Celecoxib | Celecoxib | 45 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | suppressed |
| Lovastatin | Lovastatin | 45 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 44 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 44 | 12 |
| Cephalexin | Cephalexin | 43 | 27 |
| Ozempic | Semaglutide | 41 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 28 |
| Famotidine | Famotidine | 38 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 38 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Ibu | Ibuprofen | 35 | suppressed |
| Glimepiride | Glimepiride | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 31 | 25 |
| Vascepa | Icosapent Ethyl | 31 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 30 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Carvedilol | Carvedilol | 27 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 23 |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 17 |
| Rybelsus | Semaglutide | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Ramelteon | Ramelteon | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Carbamazepine | Carbamazepine | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 16 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Methylphenidate Hcl Er (Cd) | Methylphenidate Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $147.55 · 9 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Cologuard Collection Kit, FARXIGA, TRELEGY ELLIPTA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error